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Abstract 
 
Rationale: Idiopathic pulmonary fibrosis (IPF) is a complex lung disease characterised by 
scarring of the lung that is believed to result from an atypical response to injury of the 
epithelium. Genome-wide association studies have reported signals of association 
implicating multiple pathways including host defence, telomere maintenance, signalling and 
cell-cell adhesion. 
 
Objectives: To improve our understanding of factors that increase IPF susceptibility by 
identifying previously unreported genetic associations. 
 
Methods and measurements: We conducted genome-wide analyses across three 
independent studies and meta-analysed these results to generate the largest genome-wide 
association study of IPF to date (2,668 IPF cases and 8,591 controls). We performed 
replication in two independent studies (1,457 IPF cases and 11,874 controls) and functional 
follow-up analyses (including statistical fine-mapping, investigations into gene expression 
and testing for enrichment of IPF susceptibility signals in regulatory regions) to determine 
putatively causal genes. Polygenic risk scores were used to assess the collective effect of 
variants not reported as associated with IPF. 
 
Main results: We identified and replicated three new genome-wide significant (P<5×10−8) 
signals of association with IPF susceptibility (near KIF15, MAD1L1 and DEPTOR) and confirm 
associations at 11 previously reported loci. Polygenic risk score analyses showed that the 
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combined effect of many thousands of as-yet unreported IPF susceptibility variants 
contribute to IPF susceptibility. 
 
Conclusions: The observation that decreased DEPTOR expression associates with increased 
susceptibility to IPF, supports recent studies demonstrating the importance of mTOR 
signalling in lung fibrosis. New signals of association implicating KIF15 and MAD1L1 suggest a 
possible role of mitotic spindle-assembly genes in IPF susceptibility.  
 
Abstract word count: 
 
Key words: Genetics, Epidemiology, KIF15, MAD1L1, DEPTOR 
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Introduction 
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease characterised by the build-up 
of scar tissue. It is believed that damage to the alveolar epithelium is followed by an 
aberrant wound healing response leading to the deposition of dense fibrotic tissue, reducing 
the lungs’ flexibility and inhibiting gas transfer1. Treatment options are limited and half of 
individuals diagnosed with IPF die within 3-5 years1,2. Two drugs (pirfenidone and 
nintedanib) have been approved for the treatment of IPF, but neither offer a cure and only 
slow disease progression. 
 
IPF is associated with a number of environmental and genetic factors. Identifying regions of 
the genome contributing to disease risk improves our understanding of the biological 
processes underlying IPF and helps in the development of new treatments3. To date, 
genome-wide association studies4-8 (GWAS) have reported 17 common variant (minor allele 
frequency [MAF]>5%) signals associated with IPF; stressing the importance of host defence, 
telomere maintenance, cell-cell adhesion and signalling with respect to disease 
susceptibility. The sentinel (most strongly associated) variant, rs35705950, in one of these 
signals that maps to the promoter region of the MUC5B gene, has a much larger effect on 
disease susceptibility than other reported risk variants with each copy of the risk allele 
associated with a five-fold increase in odds of disease9. Despite this, the variant rs35705950 
has a risk allele frequency of only 35% in cases (compared with 11% in the general 
population) and so does not explain all IPF risk. Rare variants (MAF<1%) in telomere-related 
and surfactant genes have also been implicated in familial pulmonary fibrosis and sporadic 
IPF10,11. 
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In this study, we aimed to identify previously unreported genetic associations with IPF to 
improve our understanding of disease susceptibility and generate new hypotheses about 
disease pathogenesis. We conducted a large GWAS of IPF susceptibility by utilising all 
European cases and controls recruited to any previously reported IPF GWAS5-8 and meta-
analysing the results. This was followed by replication in individuals not previously included 
in IPF GWAS and bioinformatic analysis of gene expression data to identify the genes 
underlying the identified association signals. As specific IPF associated variants have also 
been shown to overlap with other related respiratory traits including lung function in the 
general population, chronic obstructive pulmonary disease (COPD, with genetic effects in 
opposite directions between COPD and IPF)12-14 and interstitial lung abnormalities (ILAs, 
which might be a precursor lesion for IPF)15, we tested for association of the IPF 
susceptibility variants with these respiratory phenotypes in independent datasets. Finally, 
using polygenic risk scores, we tested whether there was a still substantial contribution to 
IPF risk from genetic variants with as-yet unconfirmed associations with IPF susceptibility.  
 
Some of the results of these studies have been previously reported in the form of an 
abstract and preprint16-18. 
 
Methods 
Study cohorts 
We analysed genome-wide data from three previously described independent IPF case-
control collections (named here as the Chicago5, Colorado6 and UK8 studies, please refer to 
Appendix for summaries of these collections). Two more independent case-control 
collections (named here as the UUS and Genentech studies) were included as replication 
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datasets. The new UUS study recruited cases from the USA, UK and Spain and selected 
controls from UK Biobank19 (full details on the recruitment, genotyping and quality control of 
UUS cases and controls can be found in the Appendix). The previously described20 
Genentech study consisted of cases from three IPF clinical trials and controls from four non-
IPF clinical trials (Appendix). All studies were restricted to unrelated individuals of European 
ancestry and we applied stringent quality control measures (full details of the quality control 
measures of each study can be found in the Appendix and Figure E1). All studies diagnosed 
cases using American Thoracic Society and European Respiratory Society guidelines21-23 and 
had appropriate institutional review board or ethics approval.  
 
Genotype data for the Colorado, Chicago, UK and UUS studies were imputed separately 
using the Haplotype Reference Consortium (HRC) r1.1 panel24 (Appendix). For individuals in 
the Genentech study, genotypes were derived from whole-genome sequencing data. 
Duplicated individuals between studies were removed (Appendix). 
 
Identification of IPF susceptibility signals 
In each of the Chicago, Colorado and UK studies separately, a genome-wide analysis of IPF 
susceptibility, using SNPTEST25 v2.5.2, was conducted adjusting for the first 10 principal 
components to account for fine-scale population structure. Only bi-allelic autosomal variants 
that had a minor allele count ≥10, were in Hardy-Weinberg Equilibrium (P>1×10−6), and were 
well imputed (imputation quality R2>0.5) in at least two studies were included. A genome-
wide meta-analysis of the association summary statistics was performed across the Chicago, 
Colorado and UK studies using R v3.5.1 (discovery stage). Conditional analyses were 
performed to identify independent association signals in each locus (Appendix). 
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Sentinel variants (defined as the variant in an association signal where no other variants 
within 1 Mb showed a stronger association) of the novel signals reaching genome-wide 
significance in the meta-analysis (P<5×10−8), and nominally significant (P<0.05) with 
consistent direction of effect in each study, were further tested in the replication samples. 
We considered novel signals to be associated with IPF susceptibility if they reached a 
Bonferroni-corrected threshold (P<0.05 / number of signals followed-up) in a meta-analysis 
of the UUS and Genentech studies (replication stage, Appendix). Previously reported signals 
with P<5×10−8 in the discovery meta-analysis were deemed as a confirmed association. 
 
Characterisation of signals and functional effects 
To further refine our association signals to include only variants with the highest 
probabilities of being causal, Bayesian fine-mapping was undertaken. This approach takes all 
variants within the associated locus and, using the GWAS association results, calculates the 
probability of each variant being the true causal variant (under the assumptions that there is 
one causal variant and that the causal variant has been measured). The probabilities are 
then combined across variants to define the smallest set of variants that is 95% likely to 
contain the causal variant (i.e. the 95% credible set) for each IPF susceptibility signal 
(Appendix).  
 
To identify which genes might be implicated by the IPF susceptibility signals, we identified 
whether any variants in the credible sets were genic coding variants and defined as 
deleterious (using VEP26). In addition, we tested to see if any of the credible set variants 
were associated with gene expression using three eQTL resources (the Lung eQTL study 
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[n=1,111]27-29, the NESDA-NTR blood eQTL database [n=4,896]30 and 48 tissues in GTEx31 [n 
between 80 and 491], Appendix). Where IPF susceptibility variants were found to be 
associated with expression levels of a gene, we tested whether the same variant was likely 
to be causal both for differences in gene expression and IPF susceptibility. We only report 
associations with gene expression where the probability of the same variant driving both the 
IPF susceptibility signal and gene expression signal exceeded 80% (Appendix). 
 
To investigate whether the IPF susceptibility variants that were in non-coding regions of the 
genome might be in regions with regulatory functions (for example, in regions of open 
chromatin), we investigated the likely functional impact of those variants using DeepSEA32. 
Taking all of the IPF susceptibility variants together, we tested for overall enrichment in 
regulatory regions specific to particular cell and tissue types using FORGE33 and GARFIELD34. 
Finally, we investigated whether the genes that were near to the IPF susceptibility variants 
were more likely to be differentially expressed between IPF cases and controls in four lung 
epithelial cell types, using SNPsea35. More details are provided in the Appendix. 
 
Shared genetic susceptibility with other respiratory traits 
As previous studies have reported shared genetic susceptibility for IPF and other lung 
traits12,13,15, we investigated whether the new and previously reported IPF susceptibility 
signals were associated with quantitative lung function measures in a GWAS of 400,102 
individuals36 or with ILA in a GWAS comparing 1,699 individuals with an ILA and 10,247 
controls37. Lung function measures investigated were, FEV1 (volume of air an individual can 
forcibly exhale in the first second), FVC (total volume of air that can be forcibly exhaled), the 
ratio FEV1/FVC (used in the diagnosis of COPD) and PEF (the peak expiratory flow). We 
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applied a Bonferroni corrected P value threshold to define variants also associated with ILA 
or lung function.  
 
Polygenic risk scores 
The contribution of as-yet unreported variants to IPF susceptibility was assessed using 
polygenic risk scores. For each individual in the UUS study, the weighted score was 
calculated as the number of risk alleles, multiplied by the effect size of the variant (as a 
weighting), summed across all variants included in the score. Effect sizes were taken from 
the discovery GWAS and independent variants selected using an LD r2≤0.1.  As we wanted to 
explore the contribution from as-yet unreported variants, we excluded variants within 1Mb 
of each IPF susceptibility locus from the risk score calculation (Appendix).  
 
The score was tested to identify whether it was associated with IPF susceptibility, adjusting 
for 10 principal components to account for fine-scale population structure, using PRSice 
v1.2538. We altered the number of variants included in the risk score calculation using a 
sliding P-threshold (PT) such that the variant had to have a P value<PT in the genome-wide 
meta-analysis to be included in the score. This allows us to explore whether variants that do 
not reach statistical significance in GWAS of current size contribute to disease susceptibility. 
We used the recommended significance threshold of P<0.001 for determining significantly 
associated risk scores38. 
 
Data availability statement 
Full summary statistics for the genome-wide meta-analysis can be downloaded at 
https://github.com/genomicsITER-developers/PFgenetics/blob/master/README.md 
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Results 
Following quality control, 541 cases and 542 controls from the Chicago study, 1,515 cases 
and 4,683 controls from the Colorado study and 612 cases and 3,366 controls from the UK 
study were available (Table 1, Figure E1) to contribute to the discovery stage of the genome-
wide susceptibility analysis (Figure 1). For the replication stage of the GWAS, after quality 
control, there were 793 cases and 10,000 controls available in the UUS study and 664 cases 
and 1,874 controls available in the Genentech study (Appendix). 
 
To identify new signals of association, we meta-analysed the genome-wide association 
results for IPF susceptibility for the Chicago, Colorado and UK discovery studies. This gave a 
maximum sample size of up to 2,668 cases and 8,591 controls for 10,790,934 well imputed 
(R2>0.5) variants with minor allele count ≥10 in each study and which were available in two 
or more of the studies (Figure E2).  
 
Three novel signals (in 3p21.31 [near KIF15, Figure 2i], 7p22.3 [near MAD1L1, Figure 2ii] and 
8q24.12 [near DEPTOR, Figure 2iii]) showed a genome-wide significant (P<5x10-8) association 
with IPF susceptibility in the discovery meta-analysis and were also significant after adjusting 
for multiple testing (P<0.01) in the replication stage comprising 1,467 IPF cases and 11,874 
controls (Tables 2 and E1). Two additional loci were genome-wide significant in the genome-
wide discovery analysis but did not reach significance in the replication studies. The sentinel 
variants of these two signals were a low frequency intronic variant in RTEL1 (MAF=2.1%, 
replication P=0.012) and a rare intronic variant in HECTD2 (MAF=0.3%, replication P=0.155).  
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Conditional analyses did not identify any additional independent association signals at the 
new or previously reported IPF susceptibility loci (Figure E5).  
 
To identify the likely causal genes for each new signal, we investigated whether any of the 
variants were also associated with changes in gene expression. The sentinel variant 
(rs78238620) of the novel signal on chromosome 3 was a low frequency variant (MAF=5%) in 
an intron of KIF15 with the minor allele being associated with increased susceptibility to IPF 
and decreased expression of KIF15 in brain tissue and the nearby gene TMEM42 in thyroid31 
(Figure E7, Tables E2 and E3i).  The IPF risk allele for the novel chromosome 7 signal 
(rs12699415, MAF=42.0%) was associated with decreased expression of MAD1L1 in heart 
tissue31 (Figure E8, Tables E2 and E3ii).  For the signal on chromosome 8, the sentinel variant 
(rs28513081) was located in an intron of DEPTOR and the IPF risk allele was associated with 
decreased expression of DEPTOR (in colon, lung and skin27-29,31) and RP11-760H22.2 (in colon 
and lung31). The risk allele was also associated with increased expression of DEPTOR (in 
whole blood30), TAF2 (in colon31), RP11-760H22.2 (in adipose31) and KB-1471A8.1 (in adipose 
and skin31, Figure E9, Tables E2 and E3iii). There were no variants predicted to be highly 
deleterious within the fine-mapped signals for any of the loci. 
 
We confirmed genome-wide significant associations with IPF susceptibility for 11 of the 17 
previously reported signals (in or near TERC, TERT, DSP, 7q22.1, MUC5B, ATP11A, IVD, 
AKAP13, KANSL1, FAM13A and DPP9; Table E1, Figure E4). The signal at FAM13A, whilst 
genome-wide significant in the discovery meta-analysis, was not significant in the Chicago 
study. This was the only signal reaching genome-wide significance in the discovery genome-
wide meta-analysis that did not reach at least nominal significance in each study in the 
11 
 
discovery analysis. Three further previously reported signals at 11p15.5 (near MUC5B) were 
no longer genome-wide significant after conditioning on the MUC5B promoter variant (Table 
E1), consistent with previous reports6,39. 
 
Of the 14 IPF susceptibility signals (i.e. the 11 previously reported signals we confirmed and 
three novel signals), the only variant predicted to have a potential functional effect on gene 
regulation through disruption of chromatin structure or transcription factor binding motifs 
(using DeepSEA) was rs2013701 (in an intron of FAM13A), which was associated with a 
change in DNase I hypersensitivity in 18 cell types and FOXA1 in the T-47D cell line (a breast 
cancer cell line derived from a pleural effusion, Table E4). The 14 IPF susceptibility signals 
were found to be enriched in DNase I hypersensitivity site regions in multiple tissues 
including foetal lung tissue (Figure E10 and E11). No enrichment in differential expression in 
airway epithelial cells between IPF cases and healthy controls was observed for the 14 IPF 
susceptibility signals when using SNPsea (Table E5).  
 
Previous studies have reported an overlap of genetic association loci between lung function 
and IPF40. We undertook a look-up of the 14 IPF susceptibility loci in the largest GWAS of 
lung function in the general population published to date36. The sentinel variants of 12 of the 
14 IPF susceptibility loci were at least nominally associated (P<0.05) with one or more lung 
function trait in general population studies (Table E6). After adjustments for multiple testing 
(P<5.2×10−4), the previously reported variants at FAM13A, DSP and IVD were associated with 
decreased FVC and variants at FAM13A, DSP, 7q22.1 (ZKSCAN1) and ATP11A were associated 
with increased FEV1/FVC. Similarly, for the three novel susceptibility variants, all showed at 
least a nominal association with decreased FVC and increased FEV1/FVC. We observed a 
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nominally significant association of the MUC5B IPF risk allele with decreased FVC and 
increased FEV1/FVC. The IPF risk alleles at MAPT were significantly associated with both 
increased FEV1 and FVC. To determine whether the variants identified for IPF susceptibility 
are driven by differences in lung function between cases and controls, we investigated 
whether variants known to be associated with lung function show an association in our IPF 
GWAS. Of the 279 variants reported36 as associated with lung function (Table E7), eight 
showed an association with lung function after corrections for multiple testing (located in or 
near MCL1, DSP, ZKSCAN1, OBFC1, IVD, MAPT and two signals in FAM13A). 
 
As interstitial lung abnormalities may be a precursor to IPF in a subset of patients, and there 
have been previous reports of shared genetic aetiology between IPF and ILA37,41,42, we 
investigated whether our three new signals, and the 11 previously reported signals, were 
associated with ILA in the largest ILA GWAS reported to date37. Eight of the IPF susceptibility 
loci were at least nominally significantly associated with either ILA or subpleural ILA with 
consistent direction of effects (i.e. the allele associated with increased IPF risk was also 
associated with increased ILA risk). The new KIF15, MAD1L1 and DEPTOR signals were not 
associated with ILA (although the rare risk allele at HECTD2 that did not replicate in our 
study showed some association with an increased risk of subpleural ILA [P=0.003] with a 
large effect size similar to that observed in the IPF discovery meta-analysis). 
 
To quantify the impact of as-yet unreported variants on IPF susceptibility, polygenic risk 
scores were calculated excluding the 14 IPF susceptibility variants (as well as all variants 
within 1Mb). The polygenic risk score was significantly associated with increased IPF 
susceptibility despite exclusion of the known genetic association signals (including MUC5B). 
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As the P-threshold (PT) for inclusion of variants in the score was increased, the risk score 
became more significant reaching a plateau at around PT=0.2 with risk score P<3.08×10−23 
and explaining around 2% of the phenotypic variation (Figure E12), suggesting that there is a 
modest but statistically significant contribution of additional as-yet undetected variants to 
IPF susceptibility. Further increasing PT beyond 0.2 did not improve the predictive accuracy 
of the risk score.  
 
 
Discussion 
We undertook the largest GWAS of IPF susceptibility to date and identified three novel 
signals of association that implicated genes not previously known to be important in IPF. 
 
The strongest evidence for the new signal on chromosome 8 implicates DEPTOR, which 
encodes the DEP Domain containing MTOR interacting protein. DEPTOR inhibits mTOR 
kinase activity as part of both the mTORC1 and mTORC2 protein complexes. The IPF risk 
allele at this locus was associated with decreased gene expression of DEPTOR in lung tissue 
(Table E2). TGFβ-induced DEPTOR suppression can stimulate collagen synthesis43 and the 
importance of mTORC1 signalling via 4E-BP1 for TGFβ induced collagen synthesis has 
recently been demonstrated in fibrogenesis44. MAD1L1, implicated by a new signal on 
chromosome 7 and eQTL analyses of non-lung tissue, is a mitotic checkpoint gene, mutations 
in which have been associated with multiple cancers including lung cancer45,46. Studies have 
shown that MAD1, a homolog of MAD1L1, can inhibit TERT activity (or possibly enforce 
expression of TERT when the promoter E-box is mutated)46,47. This could suggest that 
MAD1L1 may increase IPF susceptibility through reduced telomerase activity. Another 
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spindle-assembly related gene48, KIF15, was implicated by the new signal on chromosome 3 
(along with TMEM42).  
 
The genome-wide study also identified two signals that were not replicated after multiple 
testing adjustments. RTEL1, a gene involved in telomere elongation regulation has not 
previously been identified in an IPF GWAS, however the collective effect of rare variants in 
RTEL1 have been reported as associated with IPF susceptibility52-55. The ubiquitin E3 ligase 
encoded by HECTD2 has been shown to have a pro-inflammatory role in the lung and other 
HECTD2 variants may be protective against acute respiratory distress syndrome56. However, 
the lack of replication for these signals in our data suggests that further exploration of their 
relationship to interstitial lung diseases is warranted.  
 
By combining the largest available GWAS datasets for IPF, we were able to confirm 11 of 17 
previously reported signals. Conditional analysis at the 11p15.5 region indicated that 
previously reported signals at MUC2 and TOLLIP were not independent of the association 
with the MUC5B promoter variant. Previously reported signals at EHMT2, OBFC1 and 
MDGA2 were only found to be associated in one of the discovery studies, and showed no 
evidence of an association with IPF susceptibility in the other two discovery studies. Only the 
11 signals that we confirmed in our data were included in subsequent analyses. 
 
The IPF susceptibility signals at DSP, FAM13A, 7q22.1 (ZKSCAN1) and 17q21.31 (MAPT) have 
also been reported as associated with COPD, although with opposite effects (i.e. the allele 
associated with increased risk of IPF being associated with decreased risk of COPD). 
Spirometric diagnosis of COPD was based on a reduced FEV1/FVC ratio. In an independent 
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dataset of 400,102 individuals, eight of the IPF signals were associated with decreased FVC 
and with a comparatively weaker effect on FEV1. This is consistent with the lung function 
abnormalities associated with IPF, as well as the decreased risk of COPD. Of note, only 
around 3% of previously reported lung function signals36 also showed association with IPF 
susceptibility in our study. This suggests that whilst some IPF susceptibility variants might 
represent genes and pathways that are important in general lung health, others are likely to 
represent more disease-specific processes.  
 
Using polygenic risk scores, we demonstrated that, despite the relatively large proportion of 
disease susceptibility explained by the known genetic signals of association reported here, 
IPF is highly polygenic with potentially hundreds (or thousands) of as-yet unidentified 
variants associated with disease susceptibility.   
 
A strength of our study was the large sample size compared with previous GWAS and the 
availability of an independent replication data set. A limitation of our study was that the 
controls used were generally younger in all studies included and there were differences in 
sex and smoking distributions in some of the studies. As age, sex and smoking status were 
not available for all individuals in four of our datasets, we were unable to adjust for these 
variables without substantially reducing our sample size. However, cases and controls in the 
UUS and UK datasets were matched for age, sex and smoking. The three novel signals 
replicated in all of the discovery and replication datasets providing reassurance that the 
signals we report are robust despite differences between the data sets. As we had limited 
information beyond IPF diagnosis status for a large proportion of the individuals included in 
the studies, we cannot rule out some association with other age-related conditions that are 
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comorbid with IPF. However, other age-related conditions were not excluded from either 
the cases or controls.  For the signals near KIF15 and MAD1L1, there was substantial 
evidence for an association with gene expression in non-lung tissues but not in either of the 
two (non-fibrotic) lung tissue eQTL datasets. This could reflect cell type-specific effects that 
are missed when studying whole tissue or effects that are disease dependent. Finally, our 
study was not designed to identify rare functional variant associations. As both common and 
rare variants are known to be important in IPF susceptibility39, this is a limitation of our 
study. 
 
In summary, we report new biological insights into IPF susceptibility and demonstrate that 
further studies to identify the genetic determinants of IPF susceptibility are needed. Our 
new signals of association with IPF susceptibility provide increased support for the 
importance of mTOR signalling in pulmonary fibrosis as well as the possible implication of 
mitotic spindle-assembly genes. 
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Table 1: Demographics of study cohorts 
 
 
a Age only available for 103 Chicago controls 
b Age available for 602 UK cases 
c Sex only available for 500 Chicago cases 
d Sex only available for 510 Chicago controls 
e Smoking status only recorded for 236 UK cases 
f Smoking status only recorded for 753 IPF cases in UUS 
g Smoking status only recorded for 481 of the Genentech controls 
 
 
 Chicago Colorado UK UUS Genentech 
 Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
n 541 542 1,515 4,683 612 3,366 793 10,000 664 1,874 
Genotyping array 
/sequencing Affymetrix 6.0 SNP array 
Illumina Human 660W Quad 
BeadChip 
Affymetrix UK 
BiLEVE array 
Affymetrix UK 
BiLEVE and UK 
Biobank arrays 
Affymetrix UK 
Biobank and 
Spain Biobank 
arrays 
Affymetrix UK 
BiLEVE and UK 
Biobank arrays 
HiSeq X Ten platform (Illumina) 
Imputation panel HRC HRC HRC HRC - 
Age (mean) 68 63 a 66 - 70 b 65 69 58 68 - 
Sex (% males) 71% c 47% d 68% 49% 71% 70% 75.2% 72.1% 73.5% 27.1% 
% ever smokers 72% 42% - - 72.9% e 70% 68.7% f 68% 67.3% 18.1% g 
19 
 
Table 2 - Discovery and replication association analysis results for the five signals reaching significance in the discovery GWAS that have not previously 
reported as associated with IPF 
The minor allele is the effect allele and the minor allele frequency (MAF) is taken from across the studies used in the discovery meta-analysis. 
 
Chr Pos rsid Locus Major allele 
Minor 
allele MAF 
 
Discovery meta-analysis 
 
Replication meta-analysis 
 Meta-analysis of discovery and 
replication 
OR [95% CI] P OR [95% CI] P OR [95% CI] P 
3 44902386 rs78238620 KIF15 T A 5.3% 1.58 [1.37, 1.83] 5.12×10−10 1.48 [1.24, 1.77] 1.43×10−5 1.54 [1.38, 1.73] 4.05×10−14 
7 1909479 rs12699415 MAD1L1 G A 42.0% 1.28 [1.19, 1.37] 7.15×10−13 1.29 [1.18, 1.41] 2.27×10−8 1.28 [1.21, 1.35] 9.38×10−20 
8 120934126 rs28513081 DEPTOR A G 42.8% 0.82 [0.76, 0.87] 1.20×10−9 0.87 [0.80, 0.95] 0.002 0.83 [0.79, 0.88] 1.93×10−11 
10 93271016 rs537322302 HECTD2 C G 0.3% 7.82 [3.77, 16.2] 3.43×10−8 1.75 [0.81, 3.78] 0.155 3.85 [2.27, 6.54] 6.25×10−7 
20 62324391 rs41308092 RTEL1 G A 2.1% 2.12 [1.67, 2.69] 7.65×10−10 1.45 [1.08, 1.94] 0.012 1.82 [1.51, 2.19] 2.24×10−10 
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Table 3 – Gene expression and spirometric results for the three novel IPF susceptibility loci 
Annotation of the variant was taken from VEP. A list of all variants included in the credible sets with their annotations and eQTL results can be found in 
Table E3. For colocalisation, only genes where there was a greater than 80% probability of colocalisation between the IPF risk signal and gene expression of 
that gene are reported in this table. In the colocalisation column, ↑ denotes that the allele that increases IPF risk was associated with increased expression 
of the gene, ↓ denotes that the IPF risk allele was associated with decreased expression of the gene and ↕ denotes that the IPF risk allele was associated 
with increased expression in some tissues and decreased expression in others. Full results from the eQTL and colocalisation analyses can be found in Table 
E2. The spirometric results for the three novel IPF risk loci are taken from Shrine et al using the allele associated with increased IPF risk as the effect allele 
with β being the change in Z-score units. Results for all IPF risk variants can be found in Table E6. 
 
Chr rsid of  sentinel variant Annotation 
eQTL FEV1 FVC FEV1 / FVC 
Lung tissue Non-lung tissue 
β 
[95% CI] P 
β 
[95% CI] P 
β 
[95% CI] P 
3 rs78238620 Intron (KIF15) - ↓ KIF15 
↓ TMEM42  
−0.011 
[−0.022, 0.000] 0.069 
−0.022 
[-0.033, 0.011] 2.92×10
−4 
0.017 
[0.006, 0.028] 0.005 
7 rs12699415 Intron (MAD1L1) - ↓ MAD1L1 
−0.007 
[−0.012, −0.002] 0.011 
−0.011 
[−0.016, −0.007] 1.41×10
−5 
0.008 
[0.003, 0.012] 0.005 
8 rs28513081 Intron (DEPTOR) ↓ DEPTOR 
↓ RP11-760H22.2 
↕ DEPTOR 
↕ RP11-760H22.2 
↑ KB-1471A8.1 
↑ TAF2 
0.001 
[−0.004, 0.006] 0.822 
−0.005 
[−0.010, −0.001] 0.045 
0.011 
[0.006, 0.016] 4.22×10
−5 
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Figure 1 - Manhattan plot of discovery analysis results 
X axis shows chromosomal position and the y axis shows the −log(P value) for each variant in the discovery genome-wide analysis. The red line shows 
genome-wide significance (P<5×10-8) and variants in green met the criteria for further study in the replication analysis (i.e. reached genome-wide 
significance in the discovery meta-analysis and had P<0.05 and consistent direction of effects in each study). Genes labelled in grey are previously reported 
signals that reach significance in the discovery genome-wide meta-analysis. Genes labelled in black are the novel signals identified in the discovery analysis 
that reach genome-wide significance when meta-analysing discovery and replication samples. The signals which did not replicate are shown by red labels. 
For ease of visualisation the y axis has been truncated at 25. 
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Figure 2 - Region plots of three novel IPF susceptibility loci from discovery genome-wide meta-
analysis 
Each point represents a variant with chromosomal position on the x axis and the −log(P value) on the 
y axis. Variants are coloured in by LD with the sentinel variant. Blue lines show the recombination 
rate and gene locations are shown at the bottom of the plot. Region plots are shown for the three 
replicated novel IPF susceptibility loci, i.e. i) the susceptibility signal on chromosome 3 near KIF15, ii) 
the susceptibility signal on chromosome 7 near MAD1L1 and iii) the susceptibility signal on 
chromosome 8 near DEPTOR. 
24 
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